Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
26.22
+0.83 (3.27%)
Feb 6, 2026, 4:00 PM EST - Market closed
Assembly Biosciences Employees
Assembly Biosciences had 73 employees as of December 31, 2024. The number of employees increased by 8 or 12.31% compared to the previous year.
Employees
73
Change (1Y)
8
Growth (1Y)
12.31%
Revenue / Employee
$509,466
Profits / Employee
-$528,041
Market Cap
414.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 73 | 8 | 12.31% |
| Dec 31, 2023 | 65 | -3 | -4.41% |
| Dec 31, 2022 | 68 | -34 | -33.33% |
| Dec 31, 2021 | 102 | -37 | -26.62% |
| Dec 31, 2020 | 139 | 24 | 20.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Absci | 157 |
| Kyverna Therapeutics | 129 |
| Niagen Bioscience | 104 |
| Lineage Cell Therapeutics | 77 |
| PureTech Health | 56 |
| NovaBridge Biosciences | 32 |
| Zura Bio | 30 |
| DiaMedica Therapeutics | 28 |
ASMB News
- 6 weeks ago - Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Business Wire
- 2 months ago - Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript - Seeking Alpha
- 2 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 3 months ago - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 3 months ago - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - GlobeNewsWire
- 4 months ago - Assembly Biosciences Announces Upcoming Investor Conference Participation - GlobeNewsWire
- 4 months ago - Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe - GlobeNewsWire
- 4 months ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga